Clinical Report: Sarcopenia's Role in Breast Cancer: Prognostic Implications

Overview

Sarcopenia significantly impacts breast cancer outcomes, with low muscle mass linked to poorer survival rates and increased treatment-related complications. Further research is needed to standardize assessments and interventions.

Background

Breast cancer is the most commonly diagnosed malignancy in women, and treatment outcomes can vary widely. Sarcopenia, characterized by progressive muscle loss, has emerged as a critical factor influencing treatment tolerance and long-term survival in breast cancer patients.

Data Highlights

Sarcopenia prevalence in breast cancer ranges from 12% to 49%. Low muscle mass predicts inferior overall and disease-free survival, increased chemotherapy toxicity, and postoperative morbidity.

Key Findings

• Sarcopenia prevalence in breast cancer patients is between 12% and 49%.
• Low muscle mass is associated with poorer overall and disease-free survival rates.
• Sarcopenic patients experience heightened chemotherapy toxicity and increased postoperative complications.
• Multimodal interventions, including resistance training and nutritional support, show preliminary efficacy in preserving muscle mass.

Clinical Implications

Healthcare providers should consider assessing muscle mass and strength in breast cancer patients to identify those at risk for poor outcomes.

Conclusion

Sarcopenia is a significant prognostic factor in breast cancer. Further research is essential to establish standardized approaches for assessment and treatment.

Related Resources & Content

1. A Comprehensive and Multidisciplinary Strategy for Addressing Sarcopenia in Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy, 2025 -- https://link.springer.com/article/10.1007/s00384-025-04981-z
2. Mitigating Frailty and Sarcopenia to Improve Treatment Outcomes in Lung Cancer, The ASCO Post, 2019 -- https://ascopost.com/issues/april-25-2019/mitigating-frailty-and-sarcopenia-to-improve-treatment-outcomes-in-lung-cancer/
3. The Role of Sarcopenia Evaluation in Treatment Outcomes for Patients with Hepatocellular Carcinoma, Journal of Gastroenterology, 2020 -- https://link.springer.com/article/10.1007/s00535-020-01711-w
4. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines, PMC, 2023 -- https://pmc.ncbi.nlm.nih.gov/articles/PMC8233663/?utm_source=openai
5. Prevalence and clinical implications of sarcopenia in breast cancer: a systematic review and meta-analysis, PubMed, 2023 -- https://pubmed.ncbi.nlm.nih.gov/38702479/?utm_source=openai
6. A Comprehensive and Multidisciplinary Strategy for Addressing Sarcopenia in Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy
7. The ASCO Post — Mitigating Frailty and Sarcopenia to Improve Treatment Outcomes in Lung Cancer MORE ON FRAILTY AND SARCOPENIA
8. Journal of Gastroenterology — The Role of Sarcopenia Evaluation in Treatment Outcomes for Patients with Hepatocellular Carcinoma
9. Journal of Gastroenterology — Reply to “Prognostic value of functional assessment in sarcopenia among pancreatic cancer patients”
10. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆ - PMC
11. Prevalence and clinical implications of sarcopenia in breast cancer: a systematic review and meta-analysis - PubMed
12. Randomised phase-2 screening trial of intermittent energy restriction plus resistance exercise versus resistance exercise alone during chemotherapy for advanced breast cancer | British Journal of Cancer